(Q87518363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

[Fumaric acid as therapeutic agent for multiple sclerosis] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

A Haghikia

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

R Linker

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

R Gold

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

1 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

720-726

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

Therapies for multiple sclerosis: translational achievements and outstanding needs

12 March 2020

cites work

1 reference

12 December 2020

PML in a patient treated with fumaric acid

1 reference

12 December 2020

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

1 reference

12 December 2020

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

12 December 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

12 December 2020

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

1 reference

12 December 2020

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

12 December 2020

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

1 reference

12 December 2020

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

12 December 2020

Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway.

1 reference

12 December 2020

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease

1 reference

12 December 2020

[Treatment of psoriasis vulgaris.]

1 reference

12 December 2020

Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers

1 reference

12 December 2020

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

1 reference

12 December 2020

Manufacturer's response to case reports of PML

1 reference

12 December 2020

10.1007/S00115-014-4005-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24668400%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference